Role Of F-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography In Patients With Nasal-Type Natural Killer T-Cell Lymphoma

Minli Zhou,Shuihong Zhou,Heming Han,Kui Zhao,Guangfa Wang,Yangyang Bao
2018-01-01
Abstract:We assessed the potential of F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) imaging in the diagnosis and staging of patients with nasal-type natural killer T-cell lymphoma (NKTCL). Thirty-two consecutive patients with newly diagnosed nasal-type NKTCL, who underwent pretreatment and/or posttreatment F-18-FDG PET/CT, were analyzed in this retrospective study. Among the 22 patients who underwent whole-body F-18-FDG PET/CT before initial treatment, primary lesions were found by PET/CT in two patients, and compared with CT/MRI results; PET/CT found other additional lesions and changed the Ann Arbor stage in five patients. Univariate survival analysis showed that B symptoms (P < 0.05), LDH level (P < 0.01), and treatment (P < 0.05) were significant predictors of overall survival (OS) and progression-free survival (PFS). During subsequent treatment, 18 patients underwent post-treatment F-18-FDG PET/CT, and PET/CT found disease progression in 13 patients, disease control in two, progression-free disease in two, and PET/CT found disease control and disease progression successively in the last patient. F-18-FDG PET/CT may be an effective diagnostic workup and staging tool in nasal-type NKTCL. An F-18-FDG PET/CT scan after treatment could not only predict therapeutic response but also find disease relapse or progression. SUVmax had no independent impact on PFS or OS, although this could be related to the small number of subjects included and short follow up time.
What problem does this paper attempt to address?